8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) July 10, 2008

BSD MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-10783	75-1590407
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

2188 West 2200 South

Salt Lake City, Utah 84119

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code:  (801) 972-5555

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

BSD Medical Corporation issued a press release on July 10, 2008.  A copy of the press release is hereby furnished as Exhibit 99.1 attached hereto.

Item 9.01.       Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release of BSD Medical Corporation dated July 10, 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:  July 10, 2008

By:	/s/  Hyrum A. Mead
	Hyrum A. Mead
	President

EXHIBIT INDEX

Exhibit No. Description 99.1 Press Release of BSD Medical Corporation dated July 10, 2008

EX-99.1

Exhibit 99.1

For Immediate Release

BSD Medical’s Year-to-Date Sales Up 66% from Prior Year

SALT LAKE CITY, Utah July 10, 2008—BSD Medical Corp. (NASDAQ:BSDM) today announced that the company  has filed its third quarter 10-Q report with the Securities and Exchange Commission and has released the following highlights of year-to-date results after three quarters of its fiscal year 2008:

·   Sales were up 66% compared to the prior year

·   Gross margin rose from 41% in the prior year to 63% for the current year

·   Operating expenses decreased, compared to the prior year in spite of increased sales

·   Loss from operations decreased by 34%, compared to the prior year

·   Net cash used in operating activities decreased by 55%, compared to the prior year

A copy of the Company’s 10-Q filing can be obtained at BSD Medical’s website (www.BSDMedical.com) or through other sources.

About BSD Medical Corporation

BSD Medical Corporation designs and produces cancer therapy systems that deliver precision focused microwave and/or RF generated heat to destroy cancer cells and improve the response of cancer to radiation therapy.  Heat treatment of cancer used to improve the effectiveness of radiation therapy (or chemotherapy) is called “hyperthermia therapy.”  The company’s cancer treatment systems have been employed in many clinical trials, and have been used to treat thousands of cancer patients.  BSD Medical currently has one FDA Pre-Market (PMA) approval, and a PMA and a 510(k) submission under review by the U.S. Food and Drug administration.

One of the greatest impediments to better cancer treatment is the radiation resistance of cancer.  When used in combination with radiation therapy, clinical research has demonstrated that hyperthermia therapy can significantly increase cancer control and/or patient survival rates for some forms of cancer.  Clinical research has also shown promising results when using the company’s systems in combination with chemotherapy.  For further information, visit BSD Medical’s company website (above) or the patient website www.treatwithheat.com.

#####

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.